TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26712409

Group type: EXPERIMENTAL
Intervention: Oral administration of diluted tincture of opium (DTO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model for morphine after oral administration of DTO
Number of subjects: 0
Study: 26715594

Group type: EXPERIMENTAL
Intervention: HUAREN peritoneal dialysis fluid (packed in non-PVC bags)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baxter peritoneal dialysis fluid (packed in PVC bags)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HUAREN peritoneal dialysis fluid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baxter peritoneal dialysis fluid
Number of subjects: 0
Study: 23623449

Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Enriched Supportive Therapy (EST)
Number of subjects: 58
Study: 20805597

Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in an isolated setting
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in a classroom setting
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in an isolated setting conducted second
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 5-min psychomotor vigilance task (PVT) in both settings
Number of subjects: 75
Study: 18199300

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (DL)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (PBA)
Number of subjects: 261
Study: 16179215

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 653

Group type: COMPARATOR
Intervention: Salmeterol 50 mcg twice daily
Number of subjects: 653
Study: 12544410

Group type: EXPERIMENTAL
Intervention: Nelfinavir (part of dual nucleoside reverse transcriptase inhibitor therapy)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Full adherence to prescribed medication
Number of subjects: 108

Group type: COMPARATOR
Intervention: Full adherence vs. some nonadherence
Number of subjects: 108
Study: 10744780

Group type: EXPERIMENTAL
Intervention: 10% fat, 75% carbohydrate diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: 30% fat, 55% carbohydrate diet
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 10% fat diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: 30% fat diet
Number of subjects: 19
Study: 8898461

Group type: EXPERIMENTAL
Intervention: Integrated control measures including health education, sanitation, environmental management, and chemotherapy
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Snail intermediate host control measures
Number of subjects: 600
Study: 1500694

Group type: EXPERIMENTAL
Intervention: alpha lymphoblastoid interferon plus acyclovir
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 97
Study: 6146414

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo tablets twice daily
Number of subjects: 17
Study: 31125735

Group type: EXPERIMENTAL
Intervention: Annual screening for GGOs 4 to 5 mm (0.4% malignancy risk)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 6 to 7 mm (1.1%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 8 to 14 mm (3.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-month follow-up for GGOs 15 to 19 mm (5.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-month follow-up for GGOs greater than or equal to 20 mm (10.9%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GGOs versus solid nodules for lung-cancer death
Number of subjects: 0
Study: 29377893

Group type: EXPERIMENTAL
Intervention: Super-circuit training (SCT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuous aerobic training (CAT)
Number of subjects: 29
Study: 26868317

Group type: EXPERIMENTAL
Intervention: Training group (laparoscopy followed by arthroscopy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Training group (arthroscopy followed by laparoscopy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (laparoscopic cholecystectomy)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (diagnostic knee arthroscopy)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 72
Study: 23882088

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ibuprofen, Acetaminophen, Placebo
Number of subjects: 48
Study: 22914036

Group type: EXPERIMENTAL
Intervention: polihexanide 0.02%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: polihexanide 0.04%
Number of subjects: 20

Group type: COMPARATOR
Intervention: chlorhexidine 0.05%
Number of subjects: 20
Study: 20581724

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg for 5 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 18076221

Group type: COMPARATOR
Intervention: Group 1 (n = 24) - Stepwise periodized resistance exercise program + 100 swings/day, 3 days/week for 12 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Group 2 (n = 25) - Stepwise periodized resistance exercise program + additional rotational and full-body medicine ball exercises, 3 days/week for 12 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 16219016

Group type: EXPERIMENTAL
Intervention: Once-daily gliclazide MR
Number of subjects: 105

Group type: COMPARATOR
Intervention: Twice-daily glibenclamide
Number of subjects: 105
Study: 12169344

Group type: EXPERIMENTAL
Intervention: Carbon monoxide exposure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups (CO and control)
Number of subjects: 41
Study: 9850444

Group type: EXPERIMENTAL
Intervention: Sang-35
Number of subjects: 122

Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 122

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sang-35 and Neoral
Number of subjects: 122
Study: 7642660

Group type: EXPERIMENTAL
Intervention: High‐intensity neuromuscular electrical stimulation (alone or combined with low‐intensity)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: High‐level volitional exercise
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Low‐intensity neuromuscular electrical stimulation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combined high and low‐intensity neuromuscular electrical stimulation
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients with autologous patellar‐ligament graft
Number of subjects: 110
Study: 2502074

Group type: EXPERIMENTAL
Intervention: Sunfural S (new oral form)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Sunfural Rectal Capsules (new soft-capsule suppository form)
Number of subjects: 101

Group type: COMPARATOR
Intervention: existing drugs
Number of subjects: 101
Study: 284168

Group type: EXPERIMENTAL
Intervention: vincristine, prednisone and daunorubicin (VPD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: vincristine, prednisone and adriamycin (VPA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: vincristine and prednisone (VP)
Number of subjects: 56
Study: 30359764

Group type: EXPERIMENTAL
Intervention: Pre-emptive analgesia with paracetamol (P), ketorolac (K), and pregabalin (PR) administered 4 hours before surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 100
Study: 26725194

Group type: EXPERIMENTAL
Intervention: 400 000 IU of Vitamin A
Number of subjects: 210

Group type: COMPARATOR
Intervention: 200 000 IU of Vitamin A
Number of subjects: 210
Study: 25885548

Group type: EXPERIMENTAL
Intervention: Nutritional intervention with a neurotrophic dietary supplement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 22946523

Group type: EXPERIMENTAL
Intervention: Cold pressor stress
Number of subjects: 2
Study: 21440951

Group type: EXPERIMENTAL
Intervention: Gefitinib treatment
Number of subjects: 106

Group type: COMPARATOR
Intervention: IGFBP-3
Number of subjects: 106
Study: 19744717

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (6 biannual mass treatments)
Number of subjects: 758
Study: 17693688

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CES)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flavored water (FW)
Number of subjects: 9
Study: 15551195

Group type: EXPERIMENTAL
Intervention: mCPP infusion (serotonin agonist)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11404667

Group type: EXPERIMENTAL
Intervention: Eccentric chainring
Number of subjects: 11

Group type: COMPARATOR
Intervention: Round chainring
Number of subjects: 11
Study: 9509175

Group type: EXPERIMENTAL
Intervention: Intercostal splenic aspiration
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Abdominal splenic aspiration
Number of subjects: 270

Group type: COMPARATOR
Intervention: Bone marrow aspiration
Number of subjects: 270
Study: 8364139

Group type: EXPERIMENTAL
Intervention: Prednisolone for 4 weeks followed by thrice weekly lymphoblastoid alpha-interferon for 12 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 18
Study: 3745731

Group type: EXPERIMENTAL
Intervention: 10 mg of d‐amphetamine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 29160118

Group type: EXPERIMENTAL
Intervention: Cracking the Code (CtC) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative program targeting semantics and grammar (Control)
Number of subjects: 0
Study: 30008422

Group type: EXPERIMENTAL
Intervention: HPV16 E2 gene variations in cervical cancer patients
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: T3575G (S274A) variation in the EUR variant
Number of subjects: 251

Group type: COMPARATOR
Intervention: As variant frequency
Number of subjects: 251
Study: 27931208

Group type: EXPERIMENTAL
Intervention: MPCNL using patented suctioning sheath
Number of subjects: 182

Group type: COMPARATOR
Intervention: MPCNL traditionally using peel-away sheath
Number of subjects: 182
Study: 24621122

Group type: EXPERIMENTAL
Intervention: Formulation containing 10 mg lutein, 10 mg meso-zeaxanthin, and 2 mg zeaxanthin (Trial 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Formulation containing 10 mg lutein, 10 mg meso-zeaxanthin, 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention A; Trial 2)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Formulation containing 10 mg lutein and 2 mg zeaxanthin, 500 mg vitamin C, 400 IU vitamin E, 25 mg zinc, and 2 mg copper (Intervention B; Trial 2)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (Trial 1)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 135
Study: 22249647

Group type: EXPERIMENTAL
Intervention: Intravenous landiolol (5 μg/kg/min) followed by oral carvedilol (2.5-5 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Oral carvedilol (2.5-5 mg/day) alone
Number of subjects: 70
Study: 19200989

Group type: EXPERIMENTAL
Intervention: CDB‐2914 (10, 50, or 100 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 17405895

Group type: EXPERIMENTAL
Intervention: Glutamine (15 g twice a day for seven consecutive days every 2 weeks starting on the day of oxaliplatin infusion)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 86
Study: 16291369

Group type: EXPERIMENTAL
Intervention: 0.05% betamethasone cream applied to the distal aspect of the prepuce twice daily for the first 15 days, then once daily for 15 more days, combined with preputial gymnastics starting 1 week after topical application.
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 247
Study: 12742207

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 637

Group type: COMPARATOR
Intervention: Lichtenstein tension‐free hernia repair (operation)
Number of subjects: 637
Study: 10800627

Group type: EXPERIMENTAL
Intervention: Shortened Spanish version of the Conners Parents Rating Scale (CPRS)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Shortened Spanish version of the Conners Teacher Rating Scale (CTRS)
Number of subjects: 540
Study: 8648305

Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 224

Group type: COMPARATOR
Intervention: Cementless acetabular components
Number of subjects: 224
Study: 1335221

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (four logarithmically increasing doses)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (matched volumes)
Number of subjects: 36
Study: 6383139

Group type: EXPERIMENTAL
Intervention: Calcium chloride
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study: 2935608

Group type: EXPERIMENTAL
Intervention: Angelchik prosthesis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 47
Study: 30502026

Group type: EXPERIMENTAL
Intervention: External Rotation (ER)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Internal Rotation (IR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Healed Labrum (regardless of immobilization)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-Healed Labrum (regardless of immobilization)
Number of subjects: 50
Study: 31234791

Group type: EXPERIMENTAL
Intervention: RABWSTT with EMG biofeedback system
Number of subjects: 16
Study: 28418482

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg, single oral dose)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study: 25613634

Group type: EXPERIMENTAL
Intervention: Yiqi Houxue Bushen Decoction (treatment group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine therapy (control group)
Number of subjects: 120
Study: 23447479

Group type: COMPARATOR
Intervention: Rituximab (500 mg or 1000 mg for 1 or 2 cycles) for 24 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rituximab (500 mg or 1000 mg for 2 cycles) for 48 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (Methotrexate)
Number of subjects: 100
Study: 21757673

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) administered at 3 months post-stroke.
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: MoCA completion rates by stroke severity: 87% with mild stroke, 79% with moderate stroke, and 67% with severe stroke.
Number of subjects: 294
Study: 18287122

Group type: EXPERIMENTAL
Intervention: Music group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 17156466

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy intervention provided by midwives, including discussions on social, health or lifestyle problems, preparation and timing for pregnancy, family history, rubella immunisation, referrals for health problems, and a reminder card.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (comparison group)
Number of subjects: 0
Study: 14571006

Group type: EXPERIMENTAL
Intervention: Reiki-like healing practices
Number of subjects: 0
Study: 11113620

Group type: EXPERIMENTAL
Intervention: 7.5% alcohol administered intravenously (IV)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo administered intravenously (IV)
Number of subjects: 6
Study: 8938179

Group type: EXPERIMENTAL
Intervention: ELAD haemoperfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ELAD haemoperfusion (Group I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Group I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ELAD haemoperfusion (Group II)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (Group II)
Number of subjects: 24
Study: 1403845

Group type: EXPERIMENTAL
Intervention: Mucin containing chewing gum
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: V6
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All products (Mucin chewing gum, V6, Placebo)
Number of subjects: 43
Study: 3886207

Group type: COMPARATOR
Intervention: CU 32-085 (0.5 mg single dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CU 32-085 (8 mg daily for 3 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31886909

Group type: EXPERIMENTAL
Intervention: DBBM-C
Number of subjects: 65

Group type: COMPARATOR
Intervention: DBBM
Number of subjects: 65
Study: 30264692

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Radical prostatectomy (RP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: QuinteT Recruitment Intervention (QRI)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clinical case report forms (CRFs)
Number of subjects: 80
Study: 27766408

Group type: EXPERIMENTAL
Intervention: Knee in flexion with deflated tourniquet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Knee in extension with inflated tourniquet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Knee in extension with deflated tourniquet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Knee in flexion with inflated tourniquet
Number of subjects: 120
Study: 24879552

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (1500 shots/muscle, frequency of 5Hz, energy of 0.030 mJ/mm, one session/week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy exercise program for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy exercise program
Number of subjects: 30
Study: 22579071

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20 mg/day)
Number of subjects: 50
Study: 20195742

Group type: EXPERIMENTAL
Intervention: Early behavioral adherence (diet, self-monitoring, attendance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early dietary adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early behavioral adherence
Number of subjects: 0
Study: 18594050

Group type: EXPERIMENTAL
Intervention: Candesartan (2 weeks treatment)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Candesartan (6 months treatment)
Number of subjects: 31
Study: 16015135

Group type: EXPERIMENTAL
Intervention: Hyperoxic training (60% O2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxic training (21% O2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both H and N training
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory response at 80% VO2max
Number of subjects: 9
Study: 12665405

Group type: EXPERIMENTAL
Intervention: Long bout of exercise (LBE group, n=51)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Short bouts of exercise (SBE group, n=56)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No exercise (NE group, n=36)
Number of subjects: 143
Study: 10189126

Group type: EXPERIMENTAL
Intervention: Concurrent 5-fluorouracil (5-FU) and mitomycin-C
Number of subjects: 64

Group type: COMPARATOR
Intervention: Concurrent 5-fluorouracil (5-FU)
Number of subjects: 64
Study: 7485297

Group type: EXPERIMENTAL
Intervention: Commercially available dinoprostone gel 0.5 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Hospital-compounded formulation of 0.5 mg of prostaglandin E2 gel
Number of subjects: 134
Study: 2218419

Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg b.i.d. for seven days
Number of subjects: 188

Group type: COMPARATOR
Intervention: Erythromycin 500 mg b.i.d. for seven days
Number of subjects: 188
Study: 505427

Group type: EXPERIMENTAL
Intervention: Pulsatile elastic stockings worn for up to 17 days or until patient discharge
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no stockings)
Number of subjects: 61
Study: 31830304

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33°C for 24 hours
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33°C for 48 hours
Number of subjects: 338

Group type: COMPARATOR
Intervention: Comparison of H/I ratio between survivors and non-survivors
Number of subjects: 338
Study: 31477061

Group type: EXPERIMENTAL
Intervention: Standard model of family psychoeducation (SM-FPE) plus treatment as usual (TAU)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 74
Study: 30148718

Group type: EXPERIMENTAL
Intervention: Omalizumab (OMA) as add-on to allergen-specific immunotherapy (AIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 26867542

Group type: EXPERIMENTAL
Intervention: Continuing acute noninvasive ventilation as a long-term therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 24355200

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 456

Group type: COMPARATOR
Intervention: IFG compared to normoglycaemia
Number of subjects: 456
Study: 23413719

Group type: EXPERIMENTAL
Intervention: Trans-theoretical Model-based planned education
Number of subjects: 60
Study: 18331737

Group type: EXPERIMENTAL
Intervention: High-fat, Western meal (HIFAT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber meal (HIFIB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both meals
Number of subjects: 15
Study: 17229242

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 14962154

Group type: EXPERIMENTAL
Intervention: Medicaid reimbursement rate increase of $10 above the mean rate of approximately $75
Number of subjects: 2080
Study: 11377645

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a 22 microg subcutaneously once weekly for 2 years
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308